Table 5.

Fracture risk groups eligible for bone-sparing drugs in IOF-ECTS (96) and ACR guidelines (91) on GIOP.

IOF-ECTS		American College of Rheumatology
Premenopausal women and men < 50 years	Post-menopausal women and men ≥50 years	Adults < 40 years of age	Adults ≥ 40 years of age
Previous fracture	Previous fracture	Prior osteoporotic fracture(s)	Prior osteoporotic fracture(s)
	Age ≥70 years
	Glucocorticoid daily dose ≥7.5 mg prednisolone
	BMD T-score ≤ -1.5	BMD Z-score < -3.0 or ≥10% BMD loss/year AND continuing ≥ 7.5 mg/day, ≥ 6 months	BMD T-score ≤ -2.5 in post-menopausal women or men ≥50 years
	FRAX® 10-year risk of ≥ country-specific threshold		FRAX® 10-year risk of ≥ 10% for major osteoporotic fractures, ≥ 1% for hip fractures
		Very high glucocorticoid dose*, age ≥ 30 years	Very high glucocorticoid dose*

*Very high glucocorticoid dose = initial dose ≥ 30 mg/day and cumulative annual dose > 5g (prednisolone equivalents).